BioCentury | May 27, 2020
Emerging Company Profile

Versant’s Monte Rosa debuts with $32.5M, library of molecular glues for protein degradation

...to find targets that can be readily turned into substrates for the E3 ubiquitin ligase cereblon...
...zinc-finger transcription factors AIOLOS and IKAROS. Imids act as glues between these transcription factors and cereblon...
...Warmuth Patents: None issued Targets AIOLOS (IKZF3) - IKAROS family zinc finger 3 CRBN - Cereblon...
BioCentury | May 20, 2020
Deals

Roche deal, AACR data unveil Vividion’s targeted degradation strategy

...a target of interest to another that binds one of two E3 ubiquitin ligases -- CRBN...
...and multiple kinases, and showed they were more potent than conventional targeted degraders that recruited CRBN...
...ubiquitin ligases, adaptor proteins and transcription factors. Targets BRD4 - Bromodomain containing 4 CRBN - Cereblon...
BioCentury | May 9, 2020
Product Development

With Nuevolution’s DNA-encoded libraries, Amgen takes on targeted degradation and beyond

...Deshaies said while most of the work in the targeted degradation space has focused on cereblon...
BioCentury | Mar 10, 2020
Finance

Versant builds in Basel, but also takes to Boston, with new investments and spinouts

...and Basel, Monte Rosa is exploring next-generation protein degradation therapeutics based on a library of cereblon...
BioCentury | Nov 7, 2019
Targets & Mechanisms

New cereblon substrates linked to thalidomide teratogenicity

...study from Tokyo Medical University and the University of Milan has identified two new thalidomide-dependent CRBN...
...TP63; instead, it is pursuing CRBN regulation because cancer patients resistant to imids have reduced CRBN...
...in Phase II testing for lupus and Phase I/II trial for MM. Targets CRBN - Cereblon...
BioCentury | Oct 17, 2019
Company News

Plexium debuts with $28M, aims to induce protein degradation by searching all possibilities

...Corp. (NASDAQ:CELG) work by tagging proteins for destruction by recruiting them to degradation machinery (see “Cereblon...
BioCentury | Sep 6, 2019
Emerging Company Profile

Cullgen: boosting the breadth of E3 ligases for protein degradation

...of North Carolina Chapel Hill. While E3 ligases that associate with substrate receptors vHL and CRBN...
...of corporate development, told BioCentury that Arvinas is expanding its E3 ligase repertoire beyond vHL, CRBN...
...of North Carolina, Chapel Hill, N.C. Targets vHL - von Hippel-Lindau tumor suppressor CRBN - Cereblon...
BioCentury | Aug 21, 2019
Distillery Therapeutics

Bivalent degraders of HCV NS3/4A protease complex for HCV infection

...INDICATION: Hepatitis C virus (HCV) Bivalent small molecules targeting the HCV NS3/4A protease complex and CRBN...
...generated by conjugating HCV drug Telavic telaprevir at its pyrazine ring to one of three CRBN-binding...
...complex in vitro with IC 50 values of 385, 296 and 247 nM and bound CRBN...
BioCentury | Jul 18, 2019
Financial News

Kronos parlays diverse pipeline into $105M series A

...in the space base their targeted degraders on two well-characterized E3 ligases -- vHL and cereblon...
BioCentury | Jun 19, 2019
Company News

Gilead adds targeted degradation via Nurix deal in quest to strengthen growth areas

...tag a target for degradation. "The whole field has really been running on two ligases: Cereblon...
...Hippel-Lindau tumor suppressor Allison Johnson, Staff Writer ARV-110 Arvinas Inc. Celgene Corp. Gilead Sciences Inc. Nurix Therapeutics Inc. Androgen receptor Bruton's tyrosine kinase (Btk) Cereblon (CRBN) von...
Items per page:
1 - 10 of 39